Report: Supervalu, former president settle court suit
MINNEAPOLIS, Minn. — Supervalu last week settled its suit enforcing a non-compete clause against former president Leon Bergmann, the Minneapolis/St. Paul Business Journal reported last week.
According to the report, Bergmann had resigned as president of Supervalu’s independent business organization in favor of a position with Unified Grocers. Supervalu sued to enforce its confidentiality agreements.
Details of the settlement were not disclosed.
For the full report, click here.
American Greetings offers new card line with added toy sock puppet
CLEVELAND — American Greetings has announced a new line of children’s birthday cards: The Lost Socks. This new line of cards not only provides a beloved child with a thoughtful and funny greeting, but also gives them a cute and loveable sock puppet as an added birthday gift.
“We know that consumers love to find new and exciting ways to make a child feel really special on their birthdays," said Carol Miller, executive director of new product concepts at American Greetings. "Each Lost Socks card is just bursting with personality and cheer; kids will totally become smitten with their new sock puppet friend and play with them long after their birthdays are over.”
From the mysterious realm beyond the dryer, it’s The Lost Socks. Separated from their matching pair years ago, these ready-to-wear sock puppet cards roam the laundry room of life dedicated to spreading happiness and cheer. These adorable, pun-filled sock puppets are ready to be pulled from the card and played with for even more birthday fun. Designs includeArrrgyle the Pirate, Princess Slipperfoot and Paws the Dog, each with their own personality and backstory included on the card.
Consumers can find The Lost Socks at participating drug chains, grocery stores and mass retailers nationwide, as well as in American Greetings and Carlton Cards retail stores.
Aegerion receives FDA approval for cholesterol drug, with strongest warning
CAMBRIDGE, Mass. — The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals’ cholesterol drug, Juxtapid.
The drug — an alternative treatment for patients who have a genetic predisposition to high cholesterol — will carry a boxed warning, the strongest level of FDA warning. Juxtapid will be available only through a restricted program due to risk of liver damage.
Aegerion also will conduct a post-approval study to test the long-term safety and efficacy of Juxtapid, the company said. It plans to launch the drug in January.